EP0647133A4 - Compositions and methods for enhanced drug delivery. - Google Patents

Compositions and methods for enhanced drug delivery.

Info

Publication number
EP0647133A4
EP0647133A4 EP93915319A EP93915319A EP0647133A4 EP 0647133 A4 EP0647133 A4 EP 0647133A4 EP 93915319 A EP93915319 A EP 93915319A EP 93915319 A EP93915319 A EP 93915319A EP 0647133 A4 EP0647133 A4 EP 0647133A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
drug delivery
enhanced drug
enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915319A
Other languages
German (de)
French (fr)
Other versions
EP0647133A1 (en
Inventor
Ron L Hale
Amy Lu
Dennis Solas
Harold E Selick
Kevin R Oldenburg
Alejandro C Zaffaroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Technologies NV
Original Assignee
Affymax Technologies NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Technologies NV filed Critical Affymax Technologies NV
Publication of EP0647133A1 publication Critical patent/EP0647133A1/en
Publication of EP0647133A4 publication Critical patent/EP0647133A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
EP93915319A 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery. Withdrawn EP0647133A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89821992A 1992-06-12 1992-06-12
US898219 1992-06-12
US946393A 1993-01-27 1993-01-27
US9463 1993-01-27
PCT/US1993/005631 WO1993025197A1 (en) 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery

Publications (2)

Publication Number Publication Date
EP0647133A1 EP0647133A1 (en) 1995-04-12
EP0647133A4 true EP0647133A4 (en) 1997-10-29

Family

ID=26679515

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915319A Withdrawn EP0647133A4 (en) 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery.

Country Status (3)

Country Link
EP (1) EP0647133A4 (en)
AU (1) AU4534593A (en)
WO (1) WO1993025197A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
DK0688333T3 (en) * 1993-03-10 1999-02-08 Magainin Pharma Steroid derivatives, pharmaceutical compositions containing them and their use as antibiotics or disinfectants
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
US6468981B1 (en) 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
FR2727117A1 (en) * 1994-11-18 1996-05-24 Geffard Michel USE OF POLYLYSIN CONJUGATES FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DEGENERATIVE DISORDERS OF AUTOIMMUN CHARACTER
TR199700878T1 (en) † 1995-03-02 1998-01-21 R.P. Scherer Limited Pharmacological compositions containing inhibitors of monamine oxidase B.
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5747453A (en) * 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
IT1285405B1 (en) * 1995-06-06 1998-06-03 Alza Corp MODIFICATION OF POLYPEPTIDE DRUGS TO INCREASE FLOW BY ELECTROTRANSPORT.
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
IT1283955B1 (en) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti BIS ALCANOIL ESTERS OF CARNITINE WITH ANTIBACTERIAL, ANTIMICOTIC AND ANTIPROTZOARY ACTIVITY.
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
PT910382E (en) * 1996-04-26 2003-10-31 Genaera Corp ESCHALAMINE IN COMBINATION WITH OTHER ANTI-CANCER AGENTS FOR THE TREATMENT OF TUMORS
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
IT1299266B1 (en) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti REVERSIBLE CARNITINE PALMITOIL INHIBITORS TRANSFERRED
CA2406847C (en) 2000-04-12 2009-11-17 Genaera Corporation Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100392A1 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
GB0116047D0 (en) * 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
DE10303669A1 (en) * 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. New quaternary ammonioalkyl carbonate esters useful for treating bacterial and fungal infections and potentially useful for regulating cholesterol biosynthesis
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
DE602006005901D1 (en) * 2005-02-04 2009-05-07 Us Gov Health & Human Serv Nandrolone 17-CARBONATE
WO2008044095A1 (en) * 2006-10-11 2008-04-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
EP3176169A1 (en) 2007-01-31 2017-06-07 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
WO2008099414A1 (en) * 2007-02-13 2008-08-21 Council Of Scientific & Industrial Research NOVEL CATIONIC 17 α- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT
WO2008149181A1 (en) 2007-06-04 2008-12-11 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
CN101909581B (en) * 2007-11-14 2012-11-14 加利福尼亚大学董事会 Sterol-modified amphiphilic lipids
KR20200022525A (en) 2008-12-04 2020-03-03 충시 위 High Penetration Compositions and Their Applications
JP5733841B2 (en) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Heterocyclic compounds for the treatment of neurological and mental disorders
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
AU2011206864B2 (en) 2010-01-15 2013-12-19 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
WO2012103810A1 (en) * 2011-02-02 2012-08-09 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
FI3156056T3 (en) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising sorbitan esters
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
AU2012351747B2 (en) 2011-12-15 2016-05-12 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
JP6219918B2 (en) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
WO2013165924A1 (en) 2012-04-29 2013-11-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP6654042B2 (en) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition with improved storage stability
CN103896791B (en) * 2012-12-25 2016-12-28 广东隆赋药业股份有限公司 The preparation method of acetyl levocarnitine hydrochlorate
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN104151452B (en) * 2014-07-16 2017-02-01 西北大学 Poly(N-(2-hydroxypropyl)methacrylamide)-lonidamine macromolecular prodrug and preparation method thereof
JP7384812B2 (en) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド Aripiprazole dosing strategy
CN115851076B (en) * 2022-12-21 2023-10-31 湖北航天化学技术研究所 Graphene zinc-containing antirust paint and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023206A1 (en) * 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Antiinflammatory indomethacin di:alkylamino-ethyl ester derivs. - prepd. by heating indomethacin with an O-di:alkyl:aminoethyl-N,N'-di:isopropyl isourea in benzene
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
EP0279887A2 (en) * 1987-01-15 1988-08-31 Alfred Stracher Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
EP0289262A2 (en) * 1987-04-27 1988-11-02 Syntex Pharmaceuticals International Limited Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs
WO1991009831A1 (en) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023206A1 (en) * 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Antiinflammatory indomethacin di:alkylamino-ethyl ester derivs. - prepd. by heating indomethacin with an O-di:alkyl:aminoethyl-N,N'-di:isopropyl isourea in benzene
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
EP0279887A2 (en) * 1987-01-15 1988-08-31 Alfred Stracher Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
EP0289262A2 (en) * 1987-04-27 1988-11-02 Syntex Pharmaceuticals International Limited Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs
WO1991009831A1 (en) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9325197A1 *

Also Published As

Publication number Publication date
EP0647133A1 (en) 1995-04-12
AU4534593A (en) 1994-01-04
WO1993025197A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
EP0647133A4 (en) Compositions and methods for enhanced drug delivery.
ZA942804B (en) Oral drug delivery compositions and methods
EP0658111A4 (en) Methods for enhancing drug delivery with modified saponins.
IL109661A0 (en) Drug delivery device
EP0662851A4 (en) Drug delivery system.
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
IL110588A0 (en) Bioadhesive emulsion preparations for enhanced drug delivery
EP0596962A4 (en) Therapeutic compositions and methods.
EP0491812A4 (en) Drug delivery compositions
EP0676963A4 (en) Hyaluronic acid-urea pharmaceutical compositions and uses.
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
GB2272375B (en) Pharmaceutical composition
AU1432292A (en) Drug delivery composition and method of using the same
GB9325330D0 (en) Fluorocyclodextrin drug delivery system
EP0600754A3 (en) Constant pharmaceutical infuser.
GB9404293D0 (en) Drug delivery system
IL107122A0 (en) 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
EP0636363A3 (en) Drug delivery system.
GB2292887B (en) Drug delivery system
GB9223363D0 (en) Drug etc.delivery
ZA931775B (en) Drug delivery devices.
GB9324682D0 (en) Drug delivery system
GB9307904D0 (en) Drug delivery system
GB9303117D0 (en) Drug delivery system
ZA93286B (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI NL

RHK1 Main classification (correction)

Ipc: A61K 47/48

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19980120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980603